Activities of Rifamycin Derivatives against Wild-Type and <i>rpoB</i> Mutants of <i>Chlamydia trachomatis</i>

Minsheng Xia, Robert J. Suchland, Joli A. Carswell, John van Duzer, Debra Buxton, Kara Brown, David M. Rothstein, Walter E. Stamm

Antimicrobial Agents and Chemotherapy · 2005 · 12 citations · 11 references

DOIFull text

Open access

Concepts

Abstract

Rifalazil, a semisynthetic rifamycin, was shown previously to have exceptional potency against Chlamydia trachomatis (MIC of 0.00025 microg/ml). We therefore tested 250 additional rifamycin derivatives and identified 12 with activities that are eightfold more potent than that of rifalazil. These compounds also showed exceptional activities against rifampin-resistant strains that carry missense mutations in the rpoB gene. The antimicrobial potency and intracellular penetration of these agents suggest their potential in treatment of chlamydial infections.

References

11